| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1706-01-17 |
| Identifiers | MRN HR-EN004-SYN-TD; SSN (made up) 000-04-3318 |
| Document date | 1782-10-19 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mr. Franklin returns for his subsequent annual wellness visit, five weeks after his six-month gout and kidney review. He completed the health risk assessment before the visit. He has had no gout flare since the knee flare in July and stopped colchicine in September with his urate at target. He voids comfortably since his prostate operation in the spring. He drinks wine with dinner most days and has cut down on large dinners. He walks 30 minutes most days. He has had no falls, emergency visits, or hospital stays in the past year apart from the planned operation. He takes his medicines from a weekly organizer and has added no over-the-counter medicines. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls or emergency visits; one planned operation in the spring |
| Medicines | Adherent with a weekly organizer; no NSAIDs or new over-the-counter medicines |
| Active conditions | Gout at target, stone-free, chronic kidney disease G3a A1, hypertension controlled, prostate symptoms mild after surgery |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, better than last year |
| Psychosocial | Busy with writing and correspondence; many friends; no loneliness |
| Behavioral | Never smoker; wine with dinner four or more days a week, one or two glasses; walks 30 minutes most days; plays chess |
| Activities of daily living | Independent in bathing, dressing, eating, toileting, and transfers |
| Instrumental activities of daily living | Manages his own medicines, finances, and travel |
| Home safety | Smoke detectors working; grab bars in the bathroom; stair rails on both sides |
| Hearing and vision | Hears well in conversation; wears glasses for reading and distance; eye examination this year |
| Bladder | No leakage; gets up once at night |
| Memory | No concerns from him or his family |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 3 kg since March; no fever or fatigue |
| Eyes | Negative | No change in vision with his glasses |
| Ears, nose, mouth, and throat | Negative | No hearing loss, tinnitus, or dental pain |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Regular bowel habit; no bleeding |
| Genitourinary | Negative | Good stream; nocturia once; no blood in the urine |
| Musculoskeletal | Negative | No joint pain or swelling since July |
| Integumentary | Negative | No new or changing skin lesions |
| Neurological | Negative | No memory change, dizziness, or imbalance |
| Psychiatric | Negative | Mood cheerful; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1775-05-06 to 1782-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-03-02 to 1782-03-30 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily | Two tablets by mouth daily | Oral route | 1782-03-30 to 1782-05-18 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-05-18 | active | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 1782-03-02 to 1782-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 1782-03-02 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery | One capsule by mouth at bedtime | Oral route | 1782-03-30 to 1782-04-20 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-03-30 | active | S |
| Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 1782-05-18 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 days | Two tablets by mouth each morning for 5 days, with food | Oral route | 1782-07-06 to 1782-07-10 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1782-10-19 | Body height | 175 | cm | S |
| 1782-10-19 | Body weight | 93 | kg | S |
| 1782-10-19 | Body mass index (BMI) [Ratio] | 30.4 | kg/m2 | S |
| 1782-10-19 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1782-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1782-10-19 | Heart rate | 66 | /min | S |
| 1782-10-19 | Respiratory rate | 14 | /min | S |
| 1782-10-19 | Body temperature | 36.6 | Cel | S |
| 1782-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1782-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1782-10-19 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1782-10-19 | Total score [AUDIT-C] | 4 | {score} | S |
Vital signs recorded on 1782-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; BMI 30.4 |
| Eyes | Near and distance vision adequate with his glasses |
| Ears | Whispered-voice test passed in both ears |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear |
| Musculoskeletal | No tophi; left knee without effusion; Timed Up and Go 10 seconds |
| Neurological | Oriented; Mini-Cog 5 of 5 |
| Psychiatric | Cheerful and engaged; judgment intact |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
| Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | N40.1 | S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented. |
| Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolved | resolved | confirmed | M10.062 | S — Synthetic flare at an unscheduled visit; flares are common in the first months of urate-lowering therapy. It does not echo a dated historical attack. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | High-dose vaccine given today |
| RSV vaccine | Completed today | Single dose given today, recommended for all adults aged 75 or older |
| COVID-19 vaccine, this season | Due | Recommended at his age; he will get it at his pharmacy |
| Pneumococcal vaccine | Up to date | PCV20 three years ago; no further doses needed |
| Recombinant zoster vaccine | Up to date | Two-dose series completed four years ago |
| Tetanus booster | Up to date | Tdap eight years ago; next due in two years |
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening and counseling | Completed today | AUDIT-C 4; brief counseling given |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | No falls; Timed Up and Go 10 seconds; continue daily walking |
| Colorectal cancer screening | Not indicated | Normal colonoscopy six years ago; at 76, after discussion of the small benefit, he chose no further screening |
| Prostate cancer screening | Not indicated | Not recommended at 70 or older; prostate tissue from his operation was benign |
| Abdominal aortic aneurysm screening | Not indicated | Never smoker |
| Lung cancer screening | Not indicated | Never smoker |
| Diabetes and cholesterol | Up to date | HbA1c 5.6% in March; on atorvastatin for chronic kidney disease, without routine repeat lipid testing |
| Kidney health | Due | Yearly eGFR, urine albumin-creatinine ratio, hemoglobin, and kidney failure risk calculation due in March |
| Eye examination | Up to date | Seen by optometry this year |
Immunizations given today: High-dose influenza vaccine, 1782-1783 season; Respiratory syncytial virus vaccine, single dose [S]
Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026)
Follow-up: Serum urate and kidney tests in March with his next review. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He has a written health care directive and has named a health care agent; a copy is in the chart. He wants full treatment for reversible illness, including surgery and hospital care. He would not want prolonged mechanical ventilation or resuscitation if he could not return to reading, writing, and conversation. He will review these wishes with his agent. [S]